

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,
Petitioner,

v.

HORIZON THERAPEUTICS, INC.,
Patent Owner.

Case IPR: Unassigned
Patent 9,254,278

DECLARATION OF NEAL SONDEIMER, M.D., Ph.D.

*Inter Partes Review of USPN 9,254,278
Declaration of Neal Sondheimer, M.D., Ph.D. (Exhibit 1002)*

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	BACKGROUND	6
	A. The '278 Patent	8
	B. The Urea Cycle.....	17
	C. Prior Art Treatment Protocols Using Nitrogen Scavenging Drugs	22
III.	LEVEL OF SKILL IN THE ART	24
IV.	INTERPRETATIONS OF THE '278 PATENT	25
V.	LEGAL PRINCIPLES.....	26
VI.	GROUND 1: THE '859 PUBLICATION (INDEPENDENT CLAIM 1 AND DEPENDENT CLAIMS 2-3)	28
	A. The Prior Art and Its Holdings	28
	1. The '859 Publication.....	28
	B. Independent Claim 1 and Dependent Claims 2 and 3 Are Anticipated by the '859 Publication.....	34
	1. Independent Claim 1	34
	2. Dependent Claims 2 and 3	36
VII.	GROUND 2: FERNANDES IN VIEW OF THE '859 PUBLICATION AND LEE OR LICHTER-KONECKI, OPTIONALLY IN VIEW OF BLAU OR SIMELL (INDEPENDENT CLAIM 1 AND DEPENDENT CLAIMS 2-3)	37
	A. The Prior Art and Its Holdings	37
	1. The '859 Publication.....	37
	2. Fernandes	37
	3. Blau	41
	4. Simell	42
	5. Lee.....	42
	6. Lichter-Konecki	46
	B. Independent Claim 1 and Dependent Claims 2 and 3 Are Obvious Under 35 U.S.C. § 103(a) Over Fernandes in View of	

;

*Inter Partes Review of USPN 9,254,278
Declaration of Neal Sondheimer, M.D., Ph.D. (Exhibit 1002)*

the '859 Publication and Lee or Lichter-Konecki, Optionally in View of Blau or Simell.....	47
1. Independent Claim 1	47
2. Dependent Claims 2 and 3	52
C. Motivation to Combine	53
VIII. GROUND 3: FERNANDES IN VIEW OF THE '859 PUBLICATION, OPTIONALLY IN VIEW OF BLAU, SIMELL AND/OR LEE (INDEPENDENT CLAIMS 4, 8 AND 12 AND DEPENDENT CLAIMS 6, 7, 10, 11, 14 AND 15)	54
A. The Prior Art and Its Holdings	54
B. Independent Claims 4, 8 and 12 and Dependent Claims 6, 7, 10, 11, 14 and 15 Are Obvious Under 35 U.S.C. § 103(a) Over Fernandes in View of the '859 Publication, Optionally in View of Blau, Simell and/or Lee	54
1. Independent Claims 4, 8 and 12 Are Obvious	55
2. Dependent Claims 6, 7, 10, 11, 14 and 15	69
C. Motivation to Combine	69
IX. GROUND 4: FERNANDES IN VIEW OF THE '859 PUBLICATION AND LEE OR LICHTER-KONECKI, OPTIONALLY IN VIEW OF BLAU OR SIMELL (DEPENDENT CLAIMS 5, 9 AND 13)	71
X. ADDITIONAL REMARKS	77

*Inter Partes Review of USPN 9,254,278
Declaration of Neal Sondheimer, M.D., Ph.D. (Exhibit 1002)*

I. INTRODUCTION

I, Dr. Neal Sondheimer, M.D., Ph.D., do hereby declare and say:

1. I am a medical doctor with specialties in Pediatrics, Clinical Genetics and Clinical Biochemical Genetics. I am over the age of twenty-one (21) and competent to make this declaration. I am also qualified to give testimony under oath. The facts and opinions listed below are within my personal knowledge.

2. I am being compensated for my time in this proceeding at my standard consulting rate of \$650/hour. My compensation in no way depends on the outcome of this IPR proceeding or the content of my opinions. I am not employed by, nor receiving grant support from Par Pharmaceutical, Inc., which I refer to as “Par,” or any related companies. I am receiving compensation from Par solely for my time spent working on this matter and based only on my standard hourly consulting fees.

3. I have been asked to review U.S. Patent No. 9,254,278 (which I refer to as the '278 Patent) (Ex. 1001) and the other documents that are exhibits to the petition, and to provide my opinions on what those documents disclose.

4. I have reviewed and am familiar with, among others, the following documents:

***Inter Partes Review of USPN 9,254,278
Declaration of Neal Sondheimer, M.D., Ph.D. (Exhibit 1002)***

- a. U.S. Patent No. 9,254,278 to Scharschmidt *et al.* (“278 Patent”), filed August 3, 2015, issued February 9, 2016 is marked as Ex. 1001.
- b. U.S. Patent Publication No. 2010/0008859, filed January 7, 2009, published January 14, 2010 (“859 Publication”), which is marked as Ex. 1004.
- c. Moser, *et al.*, *Argininosuccinic Aciduria Report of Two New Cases and Demonstration of Intermittent Elevation of Blood Ammonia*, 42 *American Journal of Medicine*, 9-26 (1967) (“Moser”) which is marked as Ex. 1005.
- d. Blau, Duran, Blaskovics, Gibson (editors), *Physician’s Guide to the Laboratory Diagnosis of Metabolic Diseases*, 261-276 (2d ed. 1996) (“Blau”), which is marked as Ex. 1006.
- e. Simell, *et al.*, *Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance*, 20 *Pediatric Research*, 1117-1121 (1986) (“Simell”), which is marked as Ex. 1007.
- f. Feillet, *Alternative Pathway Therapy for Urea Cycle Disorders*, 21 *Journal of Inherited Metabolic Disease Suppl. 1*, 101-111 (1998) (“Feillet”), which is marked as Ex. 1008.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.